Nephron Clinical Practice

Original Paper

Adiponectin in Children on Peritoneal Dialysis: Relationship to Insulin Resistance and Nutritional Status

Kamariski M.a, b · Biscardi M.b · Cestino L.b · Miatello R.a · Guntsche E.b · Valles P.G.a, b

Author affiliations

aÁrea de Fisiopatología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, and bHospital Pediátrico H. Notti, Mendoza, Argentina

Keywords: Adiponectin, childrenChronic kidney diseaseContinuous ambulatory peritoneal dialysisInsulin resistanceNutritional statusOral glucose tolerance testingPeritoneal dialysis

Related Articles for ""
Nephron Clin Pract 2009;113:c24–c32
https://doi.org/10.1159/000228072

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 17, 2008
Accepted: December 05, 2008
Published online: July 10, 2009
Issue release date: August 2009

Number of Print Pages: 1
Number of Figures: 4
Number of Tables: 3


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Abstract

Aim: To study whether adiponectin and resistin serum concentrations in children on peritoneal dialysis (PD) were related to insulin resistance (IR) and anthropometric parameters of nutritional status, 11 PD patients, 9 chronic kidney disease (CKD) patients and 10 healthy children were studied. Methods: Glucose and insulin were measured during the oral glucose tolerance test. Levels of adiponectin and resistin were evaluated by ELISA, insulin by RIA. Results: In CKD patients, higher homeostasis model assessment-insulin resistance (HOMA-IR), fasting and 2-hour serum insulin levels were shown compared to control and to PD patients. Body mass index (BMI) and body fat content were severely decreased while serum adiponectin levels were significantly higher in PD patients relative to controls. No differences among groups were shown in resistin levels. On regression modeling, inverse independent associations were observed between adiponectin with percentile BMI, weight and height z-score, and with body fat content. In contrast, no relationship was found between adiponectin and IR parameters. In multiple regression analysis, adiponectin was negatively correlated with BMI. A negative association of adiponectin and resistin with glomerular filtration rate was also shown. Conclusion: A role for adiponectin in terms of its association with clinical wasting parameters in PD pediatric patients might be suggested.

© 2009 S. Karger AG, Basel



Related Articles:

References

  1. Cersimo E, Garlick P, Ferretti J: Insulin regulation of renal glucose metabolism in humans. Am J Physiol 1999;276:E78–E84.
    External Resources
  2. Alvestrand A: Carbohydrate and insulin metabolism in renal failure. Kidney Int 1997;52(suppl 62):S48–S52.
  3. Feneberg R, Sparber M, Veldhuis JD, Mehls O, Ritz E, Schaefer F: Altered temporal organization of plasma insulin oscillations in chronic renal failure. J Clin Endocrinol Metab 2002;87:1965–1973.
    External Resources
  4. Andreas F, D’Agostino R, Howard G, Mykkanen I, Russel T, Haffner S: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
    External Resources
  5. Krusinová E, Klementová M, Kopecký J, Wohl P, Kazdová L, Mlejnek P, Pravenec M, Hill M, Pelikánová T: Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects. Eur J Endocr 2007;157:443–449.
    External Resources
  6. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BH, Navis G: Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. Clin Endocrinol Metab 2007;92:1821–1826.
    External Resources
  7. Meier U, Gresssner AM: Endocrine and regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem 2004;50:1511–1525.
    External Resources
  8. Berg AH, Combs TP, Scherer PE: ACRP 30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;12:84–89.
  9. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita SH, Takuya Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Toshiaki Ohteki T, Shoko Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769.
    External Resources
  10. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
    External Resources
  11. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y: Adiponectin reduces atherosclerosis in apolipoprotein E deficient mice. Circulation 2002;106:2767–2770.
    External Resources
  12. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L: Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154–1158.
    External Resources
  13. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S: Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator activated receptor-γ action in humans. Diabetes 2001;50:2199–2202.
    External Resources
  14. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
    External Resources
  15. Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962–971.
    External Resources
  16. Amici G, Orrasch M, Da Rin G, Bocci C: Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001;17:80–83.
    External Resources
  17. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C: Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 2000;36:811–881.
    External Resources
  18. Furth SL, Stablein D, Fine RN, Power NR, Fivush BA: Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2002;109:909–913.
    External Resources
  19. Mak RH, Cheung W, Cone RD, Marks DL: Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol 2006;2:527–534.
    External Resources
  20. Trayhurn P, Bing C, Wood IS: Adipose tissue and adipokines – energy regulation from the human perspective. J Nutr 2006;136:1935S–1939S.
    External Resources
  21. Tokumura M, Nanri S, Kimura K, Tanaka T, Fujita H: Height-specific body mass index reference curves for Japanese children and adolescents 5–17 years of age. Pediatr Int 2004;46:525–530.
    External Resources
  22. Lejarraga H, Anisgstein C: Desviaciones estándar del peso para la edad de los estandares argentinos desde el nacimiento hasta la madurez. Arch Argent Pediatr 1992;90:239–242.
  23. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
    External Resources
  24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555–576.
    External Resources
  25. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22:1462–1470.
    External Resources
  26. Schwartz GJ, Haycock GB, Spitzer A: Plasma creatinine and urea concentration in children. J Pediatr 1976;88:828–832.
    External Resources
  27. Mark RHK, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron 1992;61:377–382.
    External Resources
  28. Parra A, Lopez-Uriarte A, Argote RM, Garcia G, Ledon S, Santos D: Effect of hemodialysis on glucose tolerance in children with chronic renal failure. Arch Invest Med (Mex) 1979;10:39–52.
    External Resources
  29. Lai HL, Kartal J, Mitsnefes M: Hyperinsulinemia in pediatric patients with chronic kidney disease: the role of tumor necrosis factor-α. Pediatr Nephrol 2007;22:1751–1756.
    External Resources
  30. Gillerot G, Devuyst O: Molecular mechanisms modifying the peritoneal membrane exposed to peritoneal dialysis. Clin Nephrol 2003;60:1–6.
    External Resources
  31. DeFronzo RA, Tobin JD, Rowe JW, Andres R: Glucose intolerance in uremia. Quantification of pancreatic β-cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978;63:425–435.
    External Resources
  32. Mark RHK: Insulin resistance in uremia: effect of dialysis modality. Pediatr Res 1995;40:304–308.
  33. Delaure J, Maingourd C, Couet C, Vidal S, Begros P, Lamisse F: Effect of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int 1998;18:505–511.
    External Resources
  34. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D; MMKD Study Group: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005;16:1091–1098.
    External Resources
  35. Huang JW, Yen CH J, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004;43:1047–1055.
    External Resources
  36. Guebr-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129–134.
    External Resources
  37. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
    External Resources
  38. Housova J, Anderlova K, Krizová J, Haluzikova D, Kremen J, Kimstyrová T, Papezová H, Haluzik M: Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2005;90:1366–1370.
    External Resources
  39. Castaneda-Sceppa C, Sarnak MJ, Wang X, Greene T, Madero M, Kusek JW, Beck G, Kopple JD, Levey AS, Menon V: Role of adipose tissue in determining muscle mass in patients with chronic kidney disease.J Ren Nutr2007;17:314–322.
  40. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.
    External Resources
  41. Nova E, Samartin S, Gomez S, Morande G, Marcos A: The adaptive response of the immune system to the particular malnutrition of eating disorders. Eur J Clin Nutr 20002;56(suppl 3):S34–S37.
  42. Saito K, Arata S, Hosono T, Sano Y, Takahashi K, Choi-Miura NH, Nakano Y, Tobe T, Tomita M: Adiponectin plays an important role in efficient energy usage under energy shortage. Biochim Biophys Acta 2006;1761:709–716.
    External Resources
  43. Chudek J, Adamczak M, Karkoszka H, Budziński G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003;35:2186–2189.
    External Resources
  44. Shen YY, Charlesworth JA, Kelly JJ, Peake PW: The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007;56:1201–1208.
    External Resources
  45. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–26749.
    External Resources
  46. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 2003;300:472–476.
    External Resources
  47. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR, Wilson TM, Kliewer SA, Hotamisligi GS: Adipose tissue resistin proliferator-activated receptor-γ agonists. J Biol Chem 2001;276:25651–25653.
    External Resources
  48. Schäffer A, Büchler C, Müller-Ladner U: Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004;36:702–707.
    External Resources
  49. Heilbronn LK, Rood J, Janderova L, Albu J B, Kelley DE, Ravussin E, Smith SR: Relationship between serum resistin concentrations and insulin resistance in nonobese, obese and obese diabetic subjects. J Clin Endocrinol Metab 2004;89:1844–1848.
    External Resources
  50. Kielstein JT, Becker B, Graf S, Brabat G, Haller H, Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003;42:62–66.
    External Resources
  51. Nüsken KD, Kratzsch J, Wienholz V, Stöhr W, Rascher W, Dötsch J: Circulating resistin concentrations in children depend on renal function. Nephrol Dial Transplant 2006;21:107–112.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 17, 2008
Accepted: December 05, 2008
Published online: July 10, 2009
Issue release date: August 2009

Number of Print Pages: 1
Number of Figures: 4
Number of Tables: 3


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2009, Vol.113, No. 1

August 2009

Article

Recommend This
TOP